Terapia combinada con GLP-1 e iSGLT2: ¿mayor impacto cardiorrenal?

Cardiovascular disease and chronic kidney disease (CKD) are interconnected manifestations of a common pathophysiological continuum driven by diabetes, obesity, hypertension, chronic inflammation, and metabolic dysfunction. Accordingly, the concept of cardiorenal risk has evolved from a glucose-centric model toward an integrated organ-protection strategy focused on slowing kidney disease progression, preventing cardiovascular events, and improving long-term survival. Sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have consistently demonstrated substantial cardiorenal benefits across a broad spectrum of patients, irrespective of diabetes status. Beyond glycemic control, these agents slow CKD progression, reduce hospitalization for heart failure, and lower cardiovascular mortality through complementary mechanisms, including restoration of tubuloglomerular feedback, attenuation of glomerular hyperfiltration, natriuresis, and anti-inflammatory and antifibrotic effects. Similarly, glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) have emerged as effective therapies for reducing atherosclerotic cardiovascular events while promoting weight loss, lowering blood pressure, attenuating systemic inflammation, and reducing albuminuria. Recent outcome trials have further strengthened the evidence supporting their renoprotective and cardioprotective properties, extending their therapeutic role well beyond glycemic management. The combination of SGLT2 inhibitors and GLP-1 receptor agonists represents one of the most promising advances in contemporary cardiorenometabolic medicine. Given their complementary and largely non-overlapping mechanisms of action, combination therapy has the potential to provide additive—or even synergistic—benefits in cardiovascular risk reduction, preservation of kidney function, and optimization of metabolic health. Although current evidence derives primarily from post hoc analyses, observational studies, and meta-analyses, the remarkable consistency of these findings provides a strong biological and clinical rationale. Ongoing randomized clinical trials specifically designed to evaluate this therapeutic strategy are expected to further define its role in clinical practice. Current international guidelines increasingly advocate early, individualized implementation of disease-modifying therapies, prioritizing organ protection over the correction of isolated biochemical targets. In patients with type 2 diabetes, obesity, or CKD, the combined use of SGLT2 inhibitors and GLP-1 receptor agonists has the potential to alter the natural history of cardiorenal disease, redefining preventive care and offering a tangible opportunity to reduce residual cardiorenal risk.